Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

Aart Jan van der Lely*, Alex F. Muller, Joop A. Janssen, Robert J. Davis, Kenneth A. Zib, John A. Scarlett, Steven W. Lamberts

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

106 Citations (Scopus)
13 Downloads (Pure)

Abstract

We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.

Original languageEnglish
Pages (from-to)478-481
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume86
Issue number2
DOIs
Publication statusPublished - Feb 2001

Bibliographical note

Copyright © 2001 by The Endocrine Society

Research programs

  • EMC 02-01-38-01-01

Fingerprint

Dive into the research topics of 'Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient'. Together they form a unique fingerprint.

Cite this